# SpliceBio funding rounds and investors

As of 14 Oct 2026, SpliceBio has raised $135M across 1 verified round on record; latest: $135 million Series B led by EQT Life Sciences and Sanofi Ventures, announced 11 Jun 2025.

SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes.

Website: https://splice.bio  
Headquarters: BARCELONA, SPAIN  
Page: https://fireround.dev/companies/splice.bio

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-06-11 | Series B | $135 million | EQT Life Sciences, Sanofi Ventures | Asabys (Sabadell Asabys II), Gilde Healthcare, New Enterprise Associates, Novartis, Roche Venture Fund, UCB Ventures, Ysios Capital | [splice.bio](https://splice.bio/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines), [biospace.com](https://www.biospace.com/business/splicebio-nabs-135-million-series-b-to-advance-protein-splicing-medicines) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.